Table 1.
Onset, offset and overall exposure for faster aspart (n = 44) and insulin aspart (n = 46) after a bolus dose of 0.15 U/kg administered by CSII
| Faster aspart 1 | Insulin aspart 1 | Treatment ratio 2 (95% CI) | Treatment difference 3 (95% CI) | P | |
|---|---|---|---|---|---|
| Onset of exposure, min | |||||
| tEarly 50% Cmax | 20.7 | 32.5 | 0.64 (0.57; 0.71) | −11.8 (−14.4; −9.2) | <.001 |
| tmax | 56.6 | 82.3 | 0.69 (0.60; 0.78) | −25.7 (−34.3; −17.1) | <.001 |
| Offset of exposure, min | |||||
| tLate 50% Cmax | 137.4 | 172.9 | 0.80 (0.73; 0.86) | −35.4 (−47.0; −23.8) | <.001 |
| Overall exposure | |||||
| AUCIAsp,0‐t, pmol*h/L | 606.2 | 622.8 | 0.97 (0.90; 1.05) | NA | .477 |
| Cmax, pmol/L | 278.9 | 252.1 | 1.11 (1.03; 1.19) | NA | .010 |
NA, not applicable; t, time of first non‐positive baseline infusion corrected insulin aspart concentration in the terminal part of the profile (however, no longer than 12 hours).
1
Data are least squares means.
2
Faster aspart/insulin aspart (for onset and offset of exposure endpoints, the treatment ratio was calculated using Fieller's method).
3
Faster aspart – insulin aspart.